Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377975 · ClinicalTrials.gov registry record · Phase 2
"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
A Phase 2 study, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00377975 is a Phase 2 study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 96 participants.
The verdict
NCT00377975, a Phase 2 study, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
This study compares four treatments to see which one causes the most weight loss, fat loss, loss of abdominal fat and improvement in blood tests like cholesterol. The four treatments are: Placebo, Ephedrine plus caffeine, Pioglitazone, Combined pioglitazone and ephedrine plus caffeine
Interventions
- DRUG Pioglitazone
- DRUG Caffeine
- DRUG Ephedrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00377975
The ClinicalTrials.gov registry entry for NCT00377975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pioglitazone is the first listed.
NCT00377975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00377975 about?
NCT00377975 is a clinical study titled ""Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat". This study compares four treatments to see which one causes the most weight loss, fat loss, loss of abdominal fat and improvement in blood tests like cholesterol. The four treatments are: Placebo, Ephedrine plus caffeine, Pioglitazone, Combined pioglitazone and ephedrine plus caffeine
What is the current status of trial NCT00377975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2003-01. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00377975?
The interventions under investigation include: Pioglitazone (DRUG), Caffeine (DRUG), Ephedrine (DRUG).
Who is sponsoring clinical trial NCT00377975?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.